Neuropeptide Y Y1 receptor blockade does not alter adrenergic nerve responses of the rat tail artery

European Journal of Pharmacology

Volumn 340, Issue 1, 1997, Pages 75-79

  Duckles, Sue P ^a   Adner, Mikael ^b   Edvinsson, Lars ^b   Krause, Diana N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adrenergic neurotransmission; BIBP3226; Neuropeptide Y; Neuropeptide Y receptor antagonist

Indexed keywords

NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; ARGININE; DRUG DERIVATIVE; NEUROPEPTIDE Y; NEUROPEPTIDE Y Y1 RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR;

ADRENERGIC NERVE; ADRENERGIC TRANSMISSION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MALE; NERVE POTENTIAL; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL ARTERY; ANIMAL; ARTERY; DRUG ANTAGONISM; DRUG EFFECT; ELECTROSTIMULATION; INNERVATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION; TAIL; VASCULARIZATION; VASOCONSTRICTION;

ANIMALS; ARGININE; ARTERIES; ELECTRIC STIMULATION; MALE; NEUROPEPTIDE Y; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y; SYNAPTIC TRANSMISSION; TAIL; VASOCONSTRICTION;

EID: 0031553135     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01403-9     Document Type: Article

References (19)

1. 1 receptor. Eur. J. Pharmacol. 316:1996;59-64.
2. Doods H.N., Wienen W., Entzeroth M., Rudolf K., Eberlein W., Engel W., Wieland H.A. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP3226. J. Pharmacol. Exp. Ther. 275:1995;136-142.
3. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 8:1984;225-235.
4. Erlinge D., Brunkwall J., Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: Cooperation with noradrenaline and ATP. Regul. Pept. 50:1994;259-265.
5. Gehlert D.R. Subtypes of receptors for neuropeptide Y: Implications for the targeting of therapeutics. Life Sci. 55:1994;551-562.
6. 1-selective antagonist, BIBP3226. Br. J. Pharmacol. 119:1996;1313-1318.
7. Glenn T.C., Krause D.N., Duckles S.P. Vascular responses to neuropeptide Y are greater in female than male rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;111-118.
8. Han S.P., Yang C.L., Chen X.L., Naes L., Westfall T.C. Direct evidence for the involvement of neuropeptide Y (NPY) in sympathetic nerve-mediated vasoconstriction. Soc. Neurosci. Abstr. 22:1996;1553.
9. Kasakov L., Ellis J., Kirkpatrick K., Milner P., Burnstock G. Direct evidence for concomitant release of noradrenaline, adenosine 5′-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens. J. Auton. Nerv. Syst. 22:1988;75-82.
10. Lundberg J.M. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol. Rev. 48:1996;113-178.
11. Malmström R.E., Lundberg J.M. Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: Evidence using BIBP 3226 and 3435. Eur. J. Pharmacol. 294:1995;661-668.
12. Malmström R.E., Balmér K.C., Lundberg J.M. The neuropeptide y (NPY) Y1 receptor antagonist BIBP 3226: Effects on vascular responses to exogenous and endogenous NPY in the pig in vivo. Br. J. Pharmacol. 121:1997;595-603.
13. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271:1994;R11-R13.
14. Sittiracha T., McLachlan E.M., Bell C. The innervation of the caudal artery of the rat. Neuroscience. 21:1987;647-659.
15. Tschöpl M., Miller R.C., Pelton J., Stoclet J.-C., Bucher B. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine. Br. J. Pharmacol. 110:1993;1098-1104.
16. Vu H., Budai D., Duckles S.P. Neuropeptide Y preferentially potentiates responses to adrenergic nerve stimulation by increasing the rate of conraction. J. Pharmacol. Exp. Ther. 251:1989;852-857.
17. Warner M.R., Senanayake P.deS., Ferrario C.M., Levy M.N. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ. Res. 69:1991;455-465.
18. Westfall T.C., Martin J., Chen X., Ciarleglio A., Carpentier S., Henderson K., Knuepfer M., Beinfeld M., Naes L. Cardiovascular effects and modulation of noradrenergic neurotransmission following central and peripheral administration of neuropeptide Y. Synapse. 2:1988;299-307.
19. 1 receptors. Am. J. Physiol. 270:1996;H796-H800.